Key Metrics
4.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.87
5-Year SI
5-year SI
- N/A 2-year SI
- 0.88 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
0.82
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Topics Covered
- Cancer
- Lung cancer
- Adjuvant
- Curcumin
- Chemotherapy
- Immunotherapy
- Crizotinib
- Hepatocellular carcinoma
- Overall survival
- Genotype
- Breast cancer
- Dexamethasone
- Neuroendocrine tumors
- Prostate cancer
- Gefitinib
- Respiratory system
- Standard deviation
- Sunlight
- Clinical trial
- Hepatitis B
Journal Specifications
| Overview | |
| Publisher | FUTURE MEDICINE LTD |
| Language | English |
| Frequency | Fortnightly |
| General Details | |
| Language | English |
| Frequency | Fortnightly |
| Publication Start Year | 2005 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Future Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer.
- 23 Dec 24
- Future oncology (London, England)
-
Full paper
A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.
- 23 Dec 24
- Future oncology (London, England)
-
Full paper
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?
- 23 Dec 24
- Future oncology (London, England)
-
Full paper
METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.
- 20 Dec 24
- Future oncology (London, England)
-
Full paper
Correction.
- 20 Dec 24
- Future oncology (London, England)
-
Full paper
CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.
- 20 Dec 24
- Future oncology (London, England)
Scite analysis
Powered by scite_
5k articles received 61.1k citations see all
- 1,590 Supporting
- 57,990 Mentioning
- 202 Contrasting
Editorial notices
- 2 Retractions
- 0 Withdrawals
- 44 Corrections
- 41 Errata
- 0 Expression of Concern
FAQs
How long has Future Oncology been actively publishing?
Future Oncology has been in operation since 2005 till date.
What is the publishing frequency of Future Oncology ?
Future Oncology published with a Fortnightly frequency.
How many articles did Future Oncology publish last years ?
In 2024, Future Oncology published 303 articles.
What is the eISSN & pISSN for Future Oncology ?
For Future Oncology,eISSN is 1744-8301 and pISSN is1479-6694.
What is Citescore for Future Oncology ?
Citescore for Future Oncology is 4.9.
What is SNIP score for Future Oncology ?
SNIP score for Future Oncology is 0.82.
Who is the publisher of Future Oncology ?
FUTURE MEDICINE LTD is the publisher of Future Oncology.